Clinical Trials Logo

Ocular Hypertension clinical trials

View clinical trials related to Ocular Hypertension.

Filter by:

NCT ID: NCT00471380 Completed - Glaucoma Clinical Trials

A Phase IV Study of Travoprost + Brinzolamide to Treat Glaucoma or Ocular Hypertension

Start date: March 2007
Phase: Phase 4
Study type: Interventional

Double blind, crossover randomized, multicentric study to compare efficacy and tolerability of concomitant administration of travoprost and brinzolamide versus timolol-dorzolamide fixed combination in patients with glaucoma or ocular hypertension

NCT ID: NCT00471068 Terminated - Ocular Hypertension Clinical Trials

Study of Travatan and Cosopt in Primary Open-Angle Glaucoma or Ocular Hypertension

Start date: March 2007
Phase: Phase 4
Study type: Interventional

To compare the efficacy and safety in patients treated with travoprost versus dorzolamide/timolol maleate combination in patients with open-angle glaucoma or ocular hypertension

NCT ID: NCT00465803 Completed - Ocular Hypertension Clinical Trials

A Phase IIIb Study of DuoTrav to Treat Glaucoma or Ocular Hypertension

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The purpose of this study is to assess patient compliance with DuoTrav versus concomitant administration of Timolol 0.5% plus TRAVATAN in patients with open-angle glaucoma or ocular hypertension.

NCT ID: NCT00465621 Completed - Ocular Hypertension Clinical Trials

Dose Response Study of AL-37807 Ophthalmic Solution in Patients With Open-Angle Glaucoma or Ocular Hypertension

Start date: March 2007
Phase: Phase 2
Study type: Interventional

The purpose of thie study is to compare the safety and IOP-lowering efficacy of AL-37807 Ophthalmic Solution 0.05%, 0.1% and 0.2% dosed QD AM to Xalatan dosed QD PM and Vehicle in patients with open-angle glaucoma or ocular hypertension

NCT ID: NCT00457795 Completed - Ocular Hypertension Clinical Trials

24-hour IOP-lowering Effect of Brimonidine 0.1%

Start date: December 2006
Phase: Phase 4
Study type: Interventional

This study will evaluate the efficacy and safety of brimonidine 0.1% three-times daily in patients with glaucoma or ocular hypertension

NCT ID: NCT00449956 Completed - Glaucoma Clinical Trials

MK0507A Clinical Study in Patients With Glaucoma and Ocular Hypertension (0507A-149)(COMPLETED)

Start date: March 2007
Phase: Phase 3
Study type: Interventional

The clinical study compares safety and efficacy of MK0507A (dorzolamide 1.0% / timolol 0.5%) with 1) timolol 0.5% and with 2) concomitant therapy with dorzolamide 1.0% / timolol 0.5% in patients with glaucoma and ocular hypertension.

NCT ID: NCT00443924 Completed - Ocular Hypertension Clinical Trials

Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma

Start date: March 2007
Phase: Phase 1
Study type: Interventional

The purpose of this trial is to evaluate the safety and tolerability of INS115644 Ophthalmic Solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma and to investigate the intraocular pressure lowering effects of INS115644 Ophthalmic Solution.

NCT ID: NCT00441883 Completed - Ocular Hypertension Clinical Trials

Dose-Finding Study Comparing the Safety and Efficacy of Latanoprost to a Novel Treatment for Glaucoma

Start date: March 2007
Phase: Phase 2
Study type: Interventional

This study will evaluate the safety and efficacy of PF 03187207.

NCT ID: NCT00440141 Completed - Glaucoma Clinical Trials

Brimonidine 0.1% Versus Brinzolamide 1% as Adjunctive Therapy to Latanoprost 0.005%

Start date: July 2006
Phase: Phase 4
Study type: Interventional

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering will be randomized to receive either brimonidine 0.1% or brinzolamide 1% three-times daily as adjunctive therapy to latanoprost 0.005%

NCT ID: NCT00440011 Completed - Glaucoma Clinical Trials

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Start date: August 2006
Phase: Phase 4
Study type: Interventional

Patients with glaucoma or ocular hypertension currently being treated with latanoprost 0.005%, and in need of additional IOP lowering, will be randomized to receive either bimatoprost 0.03% or travoprost 0.004% in place of latanoprost 0.005%